Patients’ Risk for
Patients’ Risk for
Opioid addiction has a genetic component. But which patients are at increased risk? Until now, there has been no objective way to find out.
Do. No. Harm.
You want to treat your patients experiencing acute pain as safely and effectively as possible. But when considering prescribing oral opioids, it’s important to understand that the risk for addiction is higher in some patients than others. Identification of these patients may play an important role in informed clinical decision-making when managing acute pain.
Although opioid use has declined in recent years, addiction to these drugs is still a major problem. One study found that each year, 6 percent of patients prescribed opioids for post-surgical pain continued to use the drugs three to six months after surgery—contributing to an epidemic that still causes tens of thousands of deaths annually.1
1. Brummett, et al. New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017;152(6):e170504. doi:10.1001/jamasurg.2017.0504.
Help Patients Avoid Addiction
AvertD™ tells you and your patients prior to prescribing if they may be at increased risk for OUD. While other methods of gauging opioid addiction risk, like questionnaires, are subjective and have limited clinical utility, AvertD provides an objective, data-driven assessment to integrate into existing clinical workflows and decision-making. Using AvertD for opioid addiction risk assessment can help you make more informed prescribing decisions and may help your patients avoid addiction.
Because genetics are only one factor in understanding the risk of developing OUD from using oral opioids, AvertD test results should be used in conjunction with a complete clinical evaluation to determine the appropriateness of oral opioids in a pain management plan.
Designed for Simplicity
Swab the patient’s cheek and mail the sample to our CAP-accredited and CLIA-certified lab.
Access the patient’s test results securely online after the lab receives and processes the sample.
A high or low risk result indicates your patient’s genetic risk for Opioid Use Disorder.
Accessible and Affordable
Our goal is to offer patients the lowest cost option available to them. We are working diligently to ensure AvertD is covered by most insurance companies. Depending on the patient’s insurance, their maximum out-of-pocket cost may vary. If coverage is denied or only part of the test is covered, SOLVD Health may appeal the decision on behalf of the patient. For details about coverage, please contact the patient’s insurance company. If the patient’s insurance does not pay for the test, the patient will be billed directly for $199.
We respect your privacy and that of your patients. Our lab is CAP-accredited and CLIA-certified and follows stringent medical privacy policies and practices. We adhere to the safe and secure storage of all personal health information in a way that is fully compliant with HIPAA regulations.
AvertD was clinically validated through a blinded, multi-center, longitudinal study evaluating patients after their initial exposure to prescription oral opioids for 4 to 30 days (n=385). They were evaluated at least one year post-exposure. The study design allowed for random representative sampling mirroring adults in the U.S. prescribed oral opioids.
In the study, AvertD demonstrated 82% sensitivity and 80% specificity with no statistically significant differences in clinical performance observed based on gender, age, length of follow-up from opioid exposure, race, or ethnicity. In addition, patients with a High Genetic Risk were shown to be 16x more likely to develop OUD than patients with a Low Genetic Risk.* This study demonstrated that AvertD may provide additional objective information regarding a patient’s risk of developing OUD. This information may enable patients and healthcare providers to make more informed decisions when considering the use of oral prescription opioids for between 4 and 30 days.
*Based on an OUD prevalence of 5% in the post-surgical population
Source: Donaldson K, Cardamone D, Genovese M, Garbely J, Demers L. Clinical Performance of a Gene-Based Machine Learning Classifier in Assessing Risk of Developing OUD in Subjects Taking Oral Opioids: A Prospective Observational Study. Ann Clin Lab Sci July-August 2021 vol. 51 no. 4 451-460
Objective and Actionable
The AvertD report provides a clear “High Risk” or “Low Risk” result and additional information to help the patient understand their result means.
Opioid Prescribing Resources
Learn more about safe and effective opioid prescribing.